06:29 AM EST, 12/10/2024 (MT Newswires) -- Eli Lilly and Company ( LLY ) said late Monday that its late-stage trial, which is evaluating pirtobrutinib to treat certain adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, met its primary endpoint of improved progression-free survival at primary analysis.

The study showed that pirtobrutinib was superior to the investigator's choice of alternative medication, based on an independent review committee assessment, the company said.

Patients treated with pirtobrutinib had a 46% lower risk of relapse, disease or death than in the control arm, the company said.

Pirtobrutinib also showed clinically meaningful improvements in other secondary endpoints such as event-free survival, extending the time to the next treatment or death by a median of 23.9 months versus 10.9 months in the control arm.